#	Pagina
attuale pagina	/open-h2020/projects/220147/index.html

Opendata, web and dolomites

EHDEN SIGNED

European Health Data and Evidence Network

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EHDEN project word cloud

Explore the words cloud of the EHDEN project. It provides you a very rough idea of what is the project "EHDEN" about.

health interoperable medications model share individual treatment unprecedented contained findable perform world provenance privacy local eco patient outcomes datasets combines structured patients analytical databases analytics provides network cdm scalable engaging agencies supporting disease huge services record core leverages vast types governance narratives electronic generate fair fast standardization utilize regulators stakeholders form amounts clinical participation distributed data transparent variety omop infrastructure bd4bo imi training ichom care tools generating diverse outcome big engagement volumes ohdsi reusable laboratory source galvanize ehden reproducible proven pipelines valid unstructured europe active diagnoses stakeholder standardised regulations medical platform accessible technologies integrating respecting ehr

Project "EHDEN" data sheet

The following table provides information about the project.

Coordinator	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://www.ehden.eu/
Total cost	28˙917˙357 €
EC max contribution	14˙105˙750 € (49%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2017-12-two-stage
Funding Scheme	IMI2-RIA
Starting year	2018
Duration (year-month-day)	from 2018-11-01 to 2024-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	coordinator	8˙613˙875.00
2	SYNAPSE RESEARCH MANAGEMENT PARTNERS SL SYNAPSE RESEARCH MANAGEMENT PARTNERS SL Organization address address: CALLE VELAZQUEZ 94 PLANTA 1 city: MADRID postcode: 28006 website: www.synapse-managers.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	944˙375.00
3	THE HYVE BV THE HYVE BV Organization address address: ARTHUR VAN SCHENDELSTRAAT 650 city: UTRECHT postcode: 3511 MJ website: www.thehyve.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	831˙812.00
4	ODYSSEUS DATA SERVICES SRO ODYSSEUS DATA SERVICES SRO Organization address address: NA HAVRANCE 1508/14 city: PRAHA postcode: 143 00 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA)	participant	731˙875.00
5	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	656˙312.00
6	UNIVERSIDADE DE AVEIRO UNIVERSIDADE DE AVEIRO Organization address address: CAMPUS UNIVERSITÁRIO DE SANTIAGO city: AVEIRO postcode: 3810-193 website: www.ua.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (AVEIRO)	participant	626˙250.00
7	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Organization address address: LEVEL 1A CITY TOWER PICCADILLY PLAZA city: MANCHESTER postcode: M1 4BT website: www.nice.org.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (MANCHESTER)	participant	610˙000.00
8	INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD Organization address address: 1 EVERSHOLT STREET city: LONDON postcode: NW1 2DN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	341˙875.00
9	TARTU ULIKOOL TARTU ULIKOOL Organization address address: ULIKOOLI 18 city: TARTU postcode: 51005 website: www.ut.ee contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EE (TARTU)	participant	309˙375.00
10	FORUM EUROPEEN DES PATIENTS (FPE) FORUM EUROPEEN DES PATIENTS (FPE) Organization address address: RUE DICKS 14 city: LUXEMBOURG postcode: 1417 website: http://www.eu-patient.eu/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	LU (LUXEMBOURG)	participant	236˙250.00
11	Stiftelsen WHO Collaborating Centre for International Drug Monitoring Stiftelsen WHO Collaborating Centre for International Drug Monitoring Organization address address: Bredgrand 7 city: UPPSALA postcode: S-75140 website: www.who-umc.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	203˙750.00
12	ABBVIE INC ABBVIE INC Organization address address: NORTH WAUKEGAN ROAD 1 city: NORTH CHICAGO IL postcode: 60064 website: www.abbvie.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (NORTH CHICAGO IL)	participant	0.00
13	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	0.00
14	BAYER AKTIENGESELLSCHAFT BAYER AKTIENGESELLSCHAFT Organization address address: KAISER-WILHEM-ALLEE 1 city: Leverkusen postcode: 51373 website: http://pharma.bayer.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Leverkusen)	participant	0.00
15	CELGENE MANAGEMENT SARL CELGENE MANAGEMENT SARL Organization address address: ROUTE DE PERREUX 1 city: BOUDRY postcode: 2017 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BOUDRY)	participant	0.00
16	Eli Lilly and Company Limited Eli Lilly and Company Limited Organization address address: Lilly House, Priestley Road city: Basingstoke postcode: RG24 9NL website: www.lilly.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (Basingstoke)	participant	0.00
17	INSTITUT DE RECHERCHES INTERNATIONALES SERVIER INSTITUT DE RECHERCHES INTERNATIONALES SERVIER Organization address address: RUE CARNOT 50 city: SURESNES postcode: 92284 website: www.servier.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (SURESNES)	participant	0.00
18	JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BEERSE)	participant	0.00
19	NOVARTIS PHARMA AG NOVARTIS PHARMA AG Organization address address: LICHTSTRASSE 35 city: BASEL postcode: 4056 website: www.novartis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BASEL)	participant	0.00
20	PFIZER LIMITED PFIZER LIMITED Organization address address: RAMSGATE ROAD city: SANDWICH postcode: CT13 9NJ website: www.pfizer.co.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SANDWICH)	participant	0.00
21	SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT Organization address address: Pierre Brossolette 1 city: Chilly Mazarin postcode: 91380 website: www.sanofi-aventis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Chilly Mazarin)	participant	0.00
22	UCB BIOPHARMA SRL UCB BIOPHARMA SRL Organization address address: ALLEE DE LA RECHERCHE 60 city: BRUXELLES postcode: 1070 website: www.ucb.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	0.00

Map

Project objective

Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health databases. These include structured data in the form of diagnoses, medications, laboratory test results, etc., and unstructured data in clinical narratives. The Electronic Health Data in a European Network (EHDEN) Consortium leverages these vast volumes of data to improve future clinical practice and individual patient outcomes by increasing our understanding of disease and treatment pathways. EHDEN will galvanize transparent and reproducible analytics that will generate valid real-world evidence to improve patient care, and enable medical outcomes-based research at an unprecedented scale. The EHDEN Consortium provides the infrastructure and eco-system supporting disease-specific projects in the IMI Big Data for Better Outcomes (BD4BO) programme. The core of EHDEN is the use of a common data model (OMOP-CDM), standardised outcome assessment (ICHOM), and transparent open-source analytics (OHDSI). The objective of the EHDEN consortium is to provide all the necessary services that enable a distributed European data network to perform fast, scalable and highly reproducible research, while respecting privacy regulations, local data provenance and governance. This will include services and tools to perform data standardization, analytical pipelines, tools to share study results, and tools for stakeholder engagement and training. The EHDEN Consortium combines active participation of stakeholder representatives with proven experience in: a) integrating different data types, methods and technologies to utilize diverse clinical datasets; b) platform development to make methods and datasets Findable, Accessible, Interoperable and Reusable (FAIR); and c) engaging a wide variety of stakeholders, including health technology assessment agencies, regulators and patients.

Deliverables

List of deliverables.
Report on SME Certification Procedure and Data Source Grant Awarding Procedure developed and implemented	Documents, reports	2020-04-10 23:45:23
Stakeholder mapping	Documents, reports	2020-04-10 23:45:23
First version of the Framework for quality benchmarking	Documents, reports	2020-04-10 23:45:23
Yearly Progress report on technical framework (1)	Documents, reports	2020-04-10 23:45:23
First Report on the implementation of the analytical pipeline for personalized medicine	Documents, reports	2020-04-10 23:45:23
Technical framework design and architecture	Documents, reports	2020-04-10 23:45:23
ICHOM standards defined using OMOP terminology	Documents, reports	2020-04-10 23:45:23
Selected priority therapeutic areas	Documents, reports	2020-04-10 23:45:23
Selection of use cases for personalized medicine	Documents, reports	2020-04-10 23:45:23
Ethics Advisory Board nomination	Documents, reports	2020-04-10 23:45:23
Report on key data source/s of interest for WP1 Use Cases	Documents, reports	2020-04-10 23:45:23

Take a look to the deliverables list in detail: detailed list of EHDEN deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2020	The EHDEN consortium Report on the EHDEN achievements during its foundational year (Nov 2018 - Oct 2019) published pages: , ISSN: , DOI:		2020-04-10
2019	Alina Trifan, JosÃ© LuÃs Oliveira Patient data discovery platforms as enablers of biomedical and translational research: A systematic review published pages: 103154, ISSN: 1532-0464, DOI: 10.1016/j.jbi.2019.103154	Journal of Biomedical Informatics 93	2020-04-10
2019	Reisberg Sulev Developing Computational Solutions for Personalized Medicine. published pages: , ISSN: , DOI:	27/06/2019	2020-04-10
2019	Edward Burn, James Weaver, Daniel Morales, Albert Prats-Uribe, Antonella Delmestri, Victoria Y Strauss, Ying He, Danielle E Robinson, Rafael Pinedo-Villanueva, Spyros Kolovos, Talita Duarte-Salles, William Sproviero, Dahai Yu, Michel Van Speybroeck, Ross Williams, Luis H John, Nigel Hughes, Anthony G Sena, Ruth Costello, Belay Birlie, David Culliford, Caroline O\'Leary, Henry Morgan, Theresa Burkar Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study published pages: e229-e236, ISSN: 2665-9913, DOI: 10.1016/s2665-9913(19)30075-x	The Lancet Rheumatology 1/4	2020-04-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EHDEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EHDEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors